DK3259255T3 - (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre - Google Patents
(2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre Download PDFInfo
- Publication number
- DK3259255T3 DK3259255T3 DK16708268.4T DK16708268T DK3259255T3 DK 3259255 T3 DK3259255 T3 DK 3259255T3 DK 16708268 T DK16708268 T DK 16708268T DK 3259255 T3 DK3259255 T3 DK 3259255T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyloxazole
- fluorobiphenyl
- carbonyl
- chloro
- hydroxy
- Prior art date
Links
- RRCIEZCEOIRHEB-VQIMIIECSA-N (2R,4R)-5-[4-(5-chloro-2-fluorophenyl)phenyl]-2-hydroxy-4-[(5-methyl-1,3-oxazole-2-carbonyl)amino]pentanoic acid Chemical compound ClC=1C=CC(=C(C=1)C1=CC=C(C=C1)C[C@H](C[C@H](C(=O)O)O)NC(=O)C=1OC(=CN=1)C)F RRCIEZCEOIRHEB-VQIMIIECSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118067P | 2015-02-19 | 2015-02-19 | |
| PCT/US2016/017699 WO2016133803A1 (en) | 2015-02-19 | 2016-02-12 | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3259255T3 true DK3259255T3 (da) | 2021-01-18 |
Family
ID=55456914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16708268.4T DK3259255T3 (da) | 2015-02-19 | 2016-02-12 | (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9533962B2 (OSRAM) |
| EP (1) | EP3259255B1 (OSRAM) |
| JP (1) | JP6714009B2 (OSRAM) |
| KR (1) | KR102573351B1 (OSRAM) |
| CN (1) | CN107250119B (OSRAM) |
| AU (1) | AU2016220348B2 (OSRAM) |
| BR (1) | BR112017017783A2 (OSRAM) |
| CA (1) | CA2975269C (OSRAM) |
| CO (1) | CO2017008426A2 (OSRAM) |
| CY (1) | CY1123728T1 (OSRAM) |
| DK (1) | DK3259255T3 (OSRAM) |
| ES (1) | ES2857101T3 (OSRAM) |
| HR (1) | HRP20210040T1 (OSRAM) |
| HU (1) | HUE052732T2 (OSRAM) |
| IL (1) | IL253759B (OSRAM) |
| LT (1) | LT3259255T (OSRAM) |
| MX (1) | MX370065B (OSRAM) |
| MY (1) | MY191183A (OSRAM) |
| PH (1) | PH12017501444A1 (OSRAM) |
| PL (1) | PL3259255T3 (OSRAM) |
| PT (1) | PT3259255T (OSRAM) |
| RS (1) | RS61325B1 (OSRAM) |
| RU (1) | RU2715241C2 (OSRAM) |
| SG (1) | SG11201706662YA (OSRAM) |
| SI (1) | SI3259255T1 (OSRAM) |
| SM (1) | SMT202100028T1 (OSRAM) |
| TW (1) | TWI707846B (OSRAM) |
| WO (1) | WO2016133803A1 (OSRAM) |
| ZA (1) | ZA201705487B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702749A (en) * | 2012-06-08 | 2017-01-27 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| DK3259255T3 (da) * | 2015-02-19 | 2021-01-18 | Theravance Biopharma R&D Ip Llc | (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre |
| KR102238177B1 (ko) | 2017-09-15 | 2021-04-07 | 주식회사 엘지화학 | 전지셀 및 전극 리드 제조방법 |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| KR20220028030A (ko) | 2019-07-03 | 2022-03-08 | 메르크 파텐트 게엠베하 | (s)-3-히드록시-1-(1h-인돌-5-일)-2-옥소-피롤리딘-3-카르복실산 3,5-디플루오로-벤질아미드의 제조 방법 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5977075A (en) | 1995-04-21 | 1999-11-02 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| BRPI0806700A8 (pt) | 2007-01-12 | 2019-01-22 | Novartis Ag | processo |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
| EA201101672A1 (ru) * | 2009-05-28 | 2012-06-29 | Новартис Аг | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| ES2441419T3 (es) * | 2009-07-22 | 2014-02-04 | Theravance, Inc. | Agentes antihipertensivos de doble acción basados en oxazol |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US9067883B2 (en) | 2010-01-22 | 2015-06-30 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| KR101892611B1 (ko) | 2010-12-15 | 2018-08-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프릴리신 억제제 |
| CN105061314A (zh) | 2010-12-15 | 2015-11-18 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| KR101854874B1 (ko) * | 2011-02-17 | 2018-05-04 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프릴리신 억제제로서 치환된 아미노부티릭 유도체 |
| EP2675792B1 (en) | 2011-02-17 | 2016-01-06 | Theravance Biopharma R&D IP, LLC | Substituted aminobutyric derivatives as neprilysin inhibitors |
| CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
| ES2699773T3 (es) | 2011-05-31 | 2019-02-12 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| ES2609810T3 (es) | 2012-05-31 | 2017-04-24 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina donadores de óxido nítrico |
| NZ702749A (en) | 2012-06-08 | 2017-01-27 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| US8871792B2 (en) | 2012-06-08 | 2014-10-28 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| ES2615275T3 (es) | 2012-08-08 | 2017-06-06 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
| CA2902456A1 (en) | 2013-03-05 | 2014-09-12 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| US9585882B2 (en) * | 2014-01-30 | 2017-03-07 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| CN107257785B (zh) | 2015-02-11 | 2020-07-07 | 施万生物制药研发Ip有限责任公司 | 作为脑啡肽酶抑制剂的(2s,4r)-5-(5’-氯-2’-氟联苯-4-基)-4-(乙氧基草酰基氨基)-2-羟甲基-2-甲基戊酸 |
| DK3259255T3 (da) | 2015-02-19 | 2021-01-18 | Theravance Biopharma R&D Ip Llc | (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre |
-
2016
- 2016-02-12 DK DK16708268.4T patent/DK3259255T3/da active
- 2016-02-12 MY MYPI2017702772A patent/MY191183A/en unknown
- 2016-02-12 PT PT167082684T patent/PT3259255T/pt unknown
- 2016-02-12 RU RU2017132430A patent/RU2715241C2/ru active
- 2016-02-12 SI SI201631051T patent/SI3259255T1/sl unknown
- 2016-02-12 KR KR1020177026454A patent/KR102573351B1/ko active Active
- 2016-02-12 CA CA2975269A patent/CA2975269C/en active Active
- 2016-02-12 ES ES16708268T patent/ES2857101T3/es active Active
- 2016-02-12 JP JP2017543772A patent/JP6714009B2/ja active Active
- 2016-02-12 WO PCT/US2016/017699 patent/WO2016133803A1/en not_active Ceased
- 2016-02-12 HR HRP20210040TT patent/HRP20210040T1/hr unknown
- 2016-02-12 PL PL16708268T patent/PL3259255T3/pl unknown
- 2016-02-12 LT LTEP16708268.4T patent/LT3259255T/lt unknown
- 2016-02-12 SM SM20210028T patent/SMT202100028T1/it unknown
- 2016-02-12 MX MX2017010666A patent/MX370065B/es active IP Right Grant
- 2016-02-12 EP EP16708268.4A patent/EP3259255B1/en active Active
- 2016-02-12 HU HUE16708268A patent/HUE052732T2/hu unknown
- 2016-02-12 AU AU2016220348A patent/AU2016220348B2/en not_active Ceased
- 2016-02-12 US US15/042,391 patent/US9533962B2/en active Active
- 2016-02-12 BR BR112017017783-8A patent/BR112017017783A2/pt not_active Application Discontinuation
- 2016-02-12 RS RS20210057A patent/RS61325B1/sr unknown
- 2016-02-12 CN CN201680011254.0A patent/CN107250119B/zh active Active
- 2016-02-12 SG SG11201706662YA patent/SG11201706662YA/en unknown
- 2016-02-19 TW TW105104991A patent/TWI707846B/zh active
- 2016-11-21 US US15/357,269 patent/US9872855B2/en active Active
-
2017
- 2017-07-31 IL IL253759A patent/IL253759B/en active IP Right Grant
- 2017-08-10 PH PH12017501444A patent/PH12017501444A1/en unknown
- 2017-08-14 ZA ZA2017/05487A patent/ZA201705487B/en unknown
- 2017-08-18 CO CONC2017/0008426A patent/CO2017008426A2/es unknown
- 2017-12-14 US US15/841,799 patent/US10172834B2/en active Active
-
2018
- 2018-12-03 US US16/207,501 patent/US10548879B2/en active Active
-
2019
- 2019-12-16 US US16/715,722 patent/US11033533B2/en not_active Expired - Fee Related
-
2021
- 2021-01-20 CY CY20211100045T patent/CY1123728T1/el unknown
- 2021-05-14 US US17/302,877 patent/US11642332B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266611A (en) | Converted N-(3-fluorophenyl)-pyrrolidine substances, process for their preparation and medical use thereof | |
| LT3440076T (lt) | Heterocikliniai amidai, naudingi kaip baltymų moduliatoriai | |
| LT3439672T (lt) | Stabilizuotas tirpus rsv f baltymas prieš suliejimą, skirtas naudoti rsv infekcijos profilaktikai | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| DK3325514T3 (da) | Her2-bindende proteiner baseret på di-ubiquitin-muteiner | |
| EP3248528C0 (en) | Endoscope system | |
| EP3384797A4 (en) | ELEMENT FOR SHOE AND SHOES | |
| MA46717A (fr) | Variantes de l'endonucléase homing tcra | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| ZA201705199B (en) | (2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| DK3621948T3 (da) | Amino(meth)acrylater | |
| DK3259255T3 (da) | (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre | |
| EP3600280A4 (en) | 1-AMINO-1-CYCLOPROPANECARBOXYL ACID HYDROCHLORIDE FORMULATIONS | |
| DK3585324T3 (da) | Sæt til neglekorrektion | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| HUE046116T2 (hu) | Biotin, demielinizációs neuropátiák kezelésére | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| DK3402573T3 (da) | Aminosyreholdig sammensætning | |
| EP3318575A4 (en) | Albumin-SUGAR CHAIN COMPLEX | |
| LT3337494T (lt) | Lizobaktinas, skirtas naudoti galvijų mastitui gydyti | |
| PL3153022T3 (pl) | N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid | |
| UA40680S (uk) | Пробка | |
| UA40679S (uk) | Пробка | |
| UA40560S (uk) | Пробка | |
| IT201700060894U1 (it) | Soletta perfezionata. |